New drug TAX2 targets Hard-to-Treat cancers in first human trial

NCT ID NCT07688148

Not yet recruiting Disease control Sponsor: Apmonia Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, how the drug moves through the body, and whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAX2
What this could lead to: If successful, TAX2 could offer a new treatment option for people with advanced solid tumors that have stopped responding to other therapies.
What could go wrong: This is an early-phase trial with a small number of participants. The drug may not shrink tumors or could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates